Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Cefotaxime

Cefotaxime: A Comprehensive Guide to a Powerful Third-Generation Cephalosporin

Introduction

Cefotaxime is a third-generation cephalosporin antibiotic that has become an essential tool in the treatment of serious bacterial infections. Since its introduction in the early 1980s, cefotaxime has earned a strong reputation for its broad-spectrum activity, particularly against gram-negative bacteria. It belongs to the β-lactam class of antibiotics, sharing structural similarities with penicillins and other cephalosporins but with enhanced stability against β-lactamases and improved central nervous system (CNS) penetration.

1. Chemical and Pharmacological Profile

Chemical Structure

Cefotaxime (chemical name: (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetyl]amino]-3-acetoxymethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid) has a β-lactam ring fused with a dihydrothiazine ring, typical of cephalosporins. Its side chains confer resistance to many β-lactamases and enhance its affinity for penicillin-binding proteins (PBPs).

Mechanism of Action

Cefotaxime inhibits bacterial cell wall synthesis by binding to PBPs, particularly PBP-3. This binding disrupts the final transpeptidation step of peptidoglycan synthesis, weakening the cell wall and leading to cell lysis. It is bactericidal in nature.

2. Pharmacokinetics

Absorption

Cefotaxime is not effective orally due to poor gastrointestinal absorption. It is administered intravenously (IV) or intramuscularly (IM).

Distribution

The drug distributes widely throughout body fluids and tissues, including the lungs, bones, cerebrospinal fluid (especially when meninges are inflamed), and synovial fluid.

Metabolism and Elimination

Cefotaxime is metabolized in the liver to desacetylcefotaxime, an active metabolite. It is excreted primarily through the kidneys, with around 80% of the drug (parent and metabolite) excreted in the urine.

Half-Life

The elimination half-life in healthy adults is about 1 hour, extended in renal impairment and neonates.

3. Antimicrobial Spectrum

Cefotaxime is valued for its broad-spectrum activity, especially its strong effectiveness against gram-negative organisms.

Effective Against:

Gram-Positive Bacteria

  • Streptococcus pneumoniae

  • Streptococcus pyogenes (Group A)

  • Streptococcus agalactiae (Group B)

  • Staphylococcus aureus (methicillin-sensitive)

Gram-Negative Bacteria

  • Escherichia coli

  • Klebsiella pneumoniae

  • Proteus mirabilis

  • Haemophilus influenzae

  • Neisseria meningitidis

  • Neisseria gonorrhoeae

  • Enterobacter spp.

  • Serratia marcescens

  • Salmonella and Shigella species

Limited or No Activity Against:

  • Pseudomonas aeruginosa

  • Enterococcus faecalis

  • Methicillin-resistant Staphylococcus aureus (MRSA)

  • Anaerobes (limited activity, particularly against Bacteroides fragilis)

4. Clinical Applications

Cefotaxime is used for a wide variety of infections, especially those involving hospital-acquired pathogens and serious community-acquired infections.

4.1 Respiratory Tract Infections

Cefotaxime is effective in treating community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), especially when caused by resistant gram-negative pathogens.

4.2 Central Nervous System Infections

Due to its good CSF penetration, cefotaxime is a preferred agent in the empirical treatment of bacterial meningitis, especially in children and neonates. It covers major causative organisms such as Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae.

4.3 Genitourinary Tract Infections

Cefotaxime is useful in the treatment of pyelonephritis, complicated urinary tract infections (UTIs), and gonorrhea, especially when first-line agents fail.

4.4 Intra-Abdominal Infections

When combined with a nitroimidazole (e.g., metronidazole), cefotaxime is effective for intra-abdominal sepsis, such as peritonitis or appendicitis.

4.5 Skin and Soft Tissue Infections

It is employed in cellulitis or soft tissue infections caused by susceptible organisms.

4.6 Sepsis and Bacteremia

Cefotaxime is part of empiric treatment protocols for sepsis, particularly in neonates and immunocompromised individuals.

4.7 Obstetric and Gynecologic Infections

It is also used in pelvic inflammatory disease and post-surgical gynecological infections.

5. Cefotaxime in Neonatology and Pediatrics

One of the distinguishing applications of cefotaxime is in neonatal infections, including sepsis and meningitis. Unlike ceftriaxone, cefotaxime doesn’t pose a significant risk of biliary sludging, making it safer for neonates.

6. Dosage and Administration

Adults

  • Typical dosing: 1–2 g every 8 hours IV/IM

  • Severe infections: Up to 2 g every 6 hours

Children

  • 100–150 mg/kg/day divided into 2–4 doses

Neonates

  • 50–100 mg/kg/day depending on age and severity of infection

Renal Impairment

Dose adjustments are necessary based on creatinine clearance.

7. Resistance Considerations

β-Lactamase Production

Although cefotaxime is stable against many β-lactamases, extended-spectrum β-lactamases (ESBLs) produced by E. coli, Klebsiella spp., and others can hydrolyze cefotaxime, rendering it ineffective.

Efflux Pumps and Porin Loss

Resistance may also arise from reduced drug permeability or increased efflux.

Cross-Resistance

Cross-resistance may occur among cephalosporins, limiting therapeutic options.

8. Adverse Effects

Cefotaxime is generally well tolerated, but like all antibiotics, it has potential side effects:

Common

  • Diarrhea

  • Rash

  • Injection site pain

  • Nausea

Less Common but Serious

  • Hypersensitivity reactions (anaphylaxis, urticaria)

  • Clostridioides difficile-associated diarrhea (CDAD)

  • Neutropenia or eosinophilia

  • Elevated liver enzymes

  • Seizures (especially in high doses or renal dysfunction)

9. Drug Interactions

  • Aminoglycosides: Increased nephrotoxicity risk

  • Loop diuretics: May enhance nephrotoxicity

  • Oral contraceptives: Reduced effectiveness due to gut flora disruption

  • Probenecid: Inhibits renal excretion of cefotaxime, increasing serum levels

10. Contraindications and Precautions

Contraindications

  • Known hypersensitivity to cephalosporins or β-lactam antibiotics

Cautions

  • History of penicillin allergy (possible cross-reactivity)

  • Renal impairment

  • Pregnancy Category B: Safe in pregnancy

  • Use caution in neonates, although safer than ceftriaxone

11. Comparison with Other Cephalosporins

Feature Cefotaxime Ceftriaxone Ceftazidime
Dosing Frequency Every 6–8 hrs Once/twice daily Every 8 hrs
CSF Penetration Good Excellent Good
Neonatal Use Safe Risk of biliary issues Caution needed
Pseudomonas Coverage Poor Poor Excellent

12. Future Outlook and Stewardship

Cefotaxime remains a key player in empirical therapy, especially in resource-limited settings and pediatric care. However, rising rates of resistance due to ESBLs and carbapenemase-producing organisms necessitate judicious use. Antibiotic stewardship programs emphasize appropriate indications, de-escalation strategies, and therapeutic drug monitoring when needed.

Conclusion

Cefotaxime is a cornerstone in the treatment of serious bacterial infections, valued for its broad-spectrum activity, safety profile in neonates, and excellent CNS penetration. Despite the challenges posed by rising antibiotic resistance, cefotaxime continues to be an indispensable option in clinical medicine. Proper use, combined with sensitivity testing and stewardship, ensures that this vital antibiotic remains effective for future generations.

References:

  1. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases

  2. WHO Model List of Essential Medicines

  3. Sanford Guide to Antimicrobial Therapy

  4. FDA Prescribing Information for Cefotaxime